At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 90 enrolled
Drug / intervention
Valsartan +3 moredrug
Likely dose
Valsartan 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Amlodipine in Combination With Valsartan Compared to Losartan in Combination With Hydrochlorothiazide Given for 52 Weeks on the Regression of Left Ventricular Hypertrophy in Patients With Mild to Moderate Hypertension
In Brief
A Phase 3 clinical trial evaluating Valsartan, Amlodipine, and 2 other interventions for Hypertension; Hypertrophy, Left Ventricular. Completed, enrolled 90 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of amlodipine plus valsartan in patients with hypertension and left ventricular hypertrophy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMar 2007
Primary CompletionMar 2010
TodayJul 2026
First PostedMar 13, 2007
Enrollment StartMar 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.3 years ago
Interventions
Valsartandrug
160 mg film coated tablets taken orally once daily in the morning.
Amlodipinedrug
5 mg or 10 mg tablets taken orally once daily in the morning.
Hydrochlorothiazidedrug
12.5 mg or 25 mg tablets taken orally once daily in the morning.
Losartandrug
100 mg tablets taken orally once daily in the morning.